[Diagnostic methodology for the biochemical recurrence of prostate cancer after brachytherapy].
Currently prostate cancer is the most frequent extracutaneous neoplasia in males in the USA, and second after lung cancer in our country. Over the last years the profile of prostate cancers diagnosed has changed due to the wide diffusion of PSA determination. Currently, almost 47% of prostate cancers are low risk at diagnosis. In this situation, the minimally invasive therapies such as brachytherapy have a growing acceptance in our environment. We analyze the special PSA kinetics after brachytherapy, and the difficulty entailed by the diagnosis of biochemical recurrence after brachytherapy, performing a bibliographic review of the available scientific evidence.
Novo
José F Suárez
JF
Servicio de Urología, Hospital Universitario de Bellvitge, L' Hospitalet de Llobregat, Barcelona, España. jfsuarez@csub.scs.es
López
Sergi Pastor
SP
Aguiló
Fernando Lucia
FL
Miranda
Eladio Franco
EF
D001918:Brachytherapy; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000175:diagnosis*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000532:radiotherapy*
D017430:Prostate-Specific Antigen